IMD-0354

• Description :

  IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].

• Product Name Alternative :

  IKK2 Inhibitor V

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  IKK

• Type :

  Reference compound

• Related Pathways :

  NF-κB

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/IMD-0354.html

• Purity :

  99.46

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O

• Molecular Formula :

  C15H8ClF6NO2

• Molecular Weight :

  383.67

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Tanaka A, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005 Mar 15;105 (6) :2324-31.|[2]Li YR, et al. Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs. Chem Biol Drug Des. 2017 Dec;90 (6) :1307-1311.|[3]Tanaka A, et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006 Jan 1;66 (1) :419-26.|[4]Lennikov A, et al. Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats. Mol Vis. 2012;18:2586-97.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  IKK-β

• CAS Number :

  [978-62-1]